Vitamin D3 Supplementation Ameliorates Typical Clinical Symptoms in Children with Autism Spectrum Disorder in Japan: A Case Study

Noboru Hasegawa1, Takako Yamada2 and Miyako Mochizuki3
1Department of Health and Medical Sciences, Ishikawa Prefectural Nursing University, 1-1 Gakuendai, Kahoku, Ishikawa 929-1210, Japan
2Department of Occupational Therapy, Bukkyo University, 7, Higashitoganoo-cho, Nishinokyo, Naka-ku, Kyoto 604-8418, Japan
3Kyoto Bunkyo Junior College, 80 Senzoku, Makishima-cho, Uji, Kyoto 611-0041, Japan

Abstract

Background: We studied the effects of vitamin D3 supplementation on serum levels of 25-hydroxyvitamin D and typical clinical symptoms in children with autism spectrum disorder (ASD).

Methods: We enrolled 5 male and 1 female Japanese children with ASD aged 3 years. Serum 25-hydroxy vitamin D was measured prior to and after 9 months of supplementation with oral vitamin D3 oil (2 μg/day of vitamin D3, corresponding to twice the daily requirement). The Childhood Autism Rating Scale (CARS), Short Sensory Profile (SSP), Vineland-II were used to assess the severity of autism-related traits. Data were analyzed using a Wilcoxon test.

Results: The 25-hydroxy vitamin D level was <20 ng/mL (deficient) in 2 children, 20-30 ng/mL and <30 ng/mL (insufficient) in 4 children before vitamin D3 supplementation. Our results showed that individual 25-hydroxy vitamin D levels varied significantly among individuals with supplementation, except in the child whose level was already sufficient. The number of children in the deficient group decreased from 2 to 1 (1: became sufficient), while the number in the insufficient group decreased from 4 to 3 (1: became sufficient). The CARS and SSP scores were decreased in all except in one child who had originally high 25-hydroxy vitamin D levels (28 ng/mL). Among the children in this study, vitamin D administration showed a positive effect on the “communication skills”, “ADL skills”, “social skills” or “motor skills” of two of the ASD children assessed with the Vineland-II.

Conclusion: These findings show that vitamin D supplementation might ameliorate typical clinical symptoms in children with autism spectrum disorder.

Introduction

Autism spectrum disorders (ASD) are developmental disorders associated with a high individual and social burden, but their etiology is poorly understood. The prevalence of ASD among 3-17 year-old children has suddenly increased, reaching 2.24% in a 2014 national survey in the United States [1]. The prevalence of ASD is likely to increase in Japan [2].

Vitamin D is a secosteroid associated with peripheral calcium homeostasis and nervous system function [3]. Vitamin D exists in two major forms, vitamin D2 from plants and D3 from animals. Both vitamin D2 and D3 are biologically inert and require activation through two hydroxylation processes involving 25-hydroxyvitamin D (CYP2R1) and 1α-hydroxylase (CYP27B1), located in the liver and kidney, respectively [4]. 1, 25-dihydroxyvitamin D (1, 25OHD) is a biologically active metabolite produced by two hydroxylation reaction steps in the nervous system [5]. Vitamin D modulates the central nervous system through its receptors which are expressed in neuronal and glia cells in almost all regions of the central nervous system [6].

It has been suggested that vitamin D reduces the risk of ASD. Cohort studies, have shown low neonatal vitamin D to be a possible risk factor for ASD [7, 8]. Studies have also investigated the association between vitamin D concentrations during pregnancy and total behavioral and neurodevelopmental problem [9-11]. However, prospective studies have not found an association between 25-hydroxyvitamin D (25OHD) concentration and ASD.

ASD usually appears during the first three years of life [12]. In one case report, Vitamin D supplementation led to significant reduction in core symptoms of ASD [13]. The present study was designed to investigate the effect of vitamin D3 supplementation corresponding to twice the daily requirement for 9 months on core symptoms of 3-year-old Japanese children with ASD.

Materials and Methods

Subjects and setting

Prior to the study, approval was obtained from the ethics committee of Bukkyo University (project registration number in 2018: 7). We enrolled 5 males and 1 female Japanese ASD children aged 3 years. The researchers were present at the child welfare institution (Mukunokien, Kyoto, Japan) where the study was conducted to assure the proper management of safety and confidentiality in the study. The manager of the institution invited parents to participate in the study, and all the children whose participation was requested from January to September in 2019 were enrolled. All subjects took oral vitamin D supplements (Baby D’200: 5.0μg/day of vitamin D3 oil purchased from Morishita Jintan Co., Ltd., Osaka) for 9 months.

Corresponding Author: Prof. Noboru Hasegawa, Department of Health and Medical Sciences, Ishikawa Prefectural Nursing University, 1-1 Gakuendai, Kahoku, Ishikawa 929-1210, Japan. Tel: +81-76-281-8300, Fax: +81-281-8319; E-mail: hasgwn@ishikawa-nu.ac.jp


Copyright: © 2020 Saleh et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Adaptive function test

All children were assessed for autism behavior using the Childhood Autism Rating Scale (CARS) [14]. An adaptive behavior scale (Vineland-II) [15] was used to identify communication, daily life, social and motor skills through a semi-structured interview conducted with parent and caregiver. The Short Sensory Profile (SSP) was used to quickly identify children with sensory processing problems from parent reports of sensory behaviors in their child [16].

The tests were performed by skilled occupational therapists.

SerumCa, iPTH and 25OHD

Blood was collected by venipuncture and serumCa, iPTH and 25OHD concentrations were measured by Kyoto Microbio Laboratory, (Kyoto, Japan).

Statistical analysis

The differences between before and after intervention with vitamin D3 supplements were evaluated using the Wilcoxon test. A p-value of < 0.05 was considered to be statistically significant. Analyses were carried out using SPSS 21 for Windows (IBM, Japan).

Results and Discussion

Study subjects

Characteristics of the study subjects are shown in Table 1. Age was 3 years for all the children (males, n=5 females, n=1). Ca and iPTH were within the normal range, but 25OHD was below the sufficient value (>=30ng/mL) (Table 1).

Change in serum 25OHD

Serum 25OHD was classified as normal (>=30 ng/ml), insufficient (>20 to 29.9), or deficient (<=20). In this study, the level was deficient (n=2) or insufficient (n=4). Nine-month intake of vitamin D3 supplements increased serum Ca and 25OHD concentration significantly (Figure 1). Serum Ca and iPTH were within normal range for 9 months. The vitamin D deficient group decreased from 2 children to 1 (1: became insufficient) and the insufficient group decreased from 4 children to 3 (1: became sufficient). These results suggest that vitamin D3 supplement intake increased serum 25OHD levels.

Adaptive function

The CARS and SSP scores decreased in all except one child who had originally high 25-hydroxy vitamin D levels (28 ng/mL) (Figure 2).

Table 1: Characteristics of the study subjects.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ca (mg/dL)</td>
<td>9.71±0.43</td>
</tr>
<tr>
<td>iPTH (pg/mL)</td>
<td>25.0 ±8.75</td>
</tr>
<tr>
<td>25OHD (ng/mL)</td>
<td>22.55±5.5</td>
</tr>
</tbody>
</table>

Figure 1: SerumCa, iPTH and 25OHD during intake of vitamin D3.

Figure 2: CARS and Short Sensory Profile during intake of vitamin D3.
Among the ASD children in this study, vitamin D administration had a positive effect on “communication skills”, “ADL skills”, “social skills” or “motor skills” in two children, based on the Vineland-II (Figure 3).

Many epidemiological studies have assessed the relationship between vitamin D and ASD [17]. The majority have examined the relationship between the vitamin D status of pregnant women and the risk of ASD in their children, and reported the vitamin D status of ASD children. Some studies have found no relationship between vitamin D status and ASD [18,19].

A few studies have reported the effect of vitamin D supplementation in women during pregnancy and in children with ASD. Vitamin D supplementation at adequate dose during pregnancy reduces the incidence of autism [20]. Administration of vitamin D administration to a vitamin D deficient 32-month-old boy with ASD improved his core symptoms of autism [13]. Among the children in this study, vitamin D supplementation had an ameliorative effect on “communication skills”, “ADL skills”, “social skills” or “motor skills” associated with the disorder.

Vitamin D is regarded as a hormone that is active not only in regulating blood calcium but also in brain development. Vitamin D may have a positive effect on serotonin, which affects brain development [21]. The developmental disruption of serotonin signaling may be involved in autism [22]. These results suggest that vitamin D supplementation may ameliorate clinical symptoms in ASD children.

This is a preliminary study with a very small number subjects, and it was uncontrolled. Further study with larger numbers of subjects is warranted, and could reveal optimal 25OHD levels for ameliorating ASD symptoms and preventing falls in ASD children.

Conclusion

These findings indicate that vitamin D supplementation might improve adaptive function.

Author Contributions

Dr. Hasegawa was responsible for the study conception, design, and analysis, interpretation of data, and drafting of the manuscript.

Ms. Mochizuki was responsible for data acquisition and proof reading of the manuscript, and she participated in the data analysis.

Dr. Yamada was responsible for the data acquisition and proof reading of the manuscript.

Acknowledgements

The author acknowledges Ms. Chizu Shibuya and Ms. Fumie Fukuda for then kind help.

Competing Interest

The authors declare that they have no competing interest.

References


